The global headquarters of a top-5 pharmaceutical company needed to develop a global policy strategy to support the launch of a new treatment for influenza.
A US-based biotech company required support to identify, evaluate and prioritize novel immunotherapies and targeted oncology drug candidates to supplement its clinical pipeline.
To support a mid-stage clinical development program, a top-5 pharmaceutical company engaged Shift Health to obtain an understanding of physicians’ decision-making process with alternative therapies.
A global biopharmaceutical company recognized the need to work in partnership with healthcare systems in order to realize the vital, long-term potential of a personalized approach to healthcare.
An Asian specialty healthcare company needed to assess the US market for novel image guidance medical device systems for minimally invasive cardiac interventions.
A player in the medical cannabis space required support to uncover and catalogue scientific evidence that established the link between specific cannabis-based metabolites and their therapeutic benefit.
A top-5 global biopharmaceutical company wanted to identify promising oncology drug candidates that it could in-license or acquire to bolster its oncology franchise revenues over the near term.
Recognizing the dynamic nature of the psychiatry therapeutic arena, a top-5 pharmaceutical company required support in characterizing and prioritizing the stakeholder environment to inform how Medical Affairs could work with other functions to optimize patient care.
A global pharmaceutical company wanted to identify diagnostic technologies that would support the clinical development and commercial performance of agents targeting two infectious diseases and represent potential partnership opportunities.